Das M, Musetti S, Huang L. RNA interference-based cancer drugs: the roadblocks, and the "delivery" of the promise. Nucleic Acid Ther. 2019 Apr;29(2):61-6. doi: 10.1089/nat.2018.0762
Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. Hospital Practice. 2017 Aug;45(3):111-7. doi: 10.1080/21548331.2017.1324227
Candrilli SD, Dhamane AD, Meyers JL, Kaila S. Factors associated with inpatient readmission among managed care enrollees with COPD. Hospital Practice. 2015 Oct;43(4):199-207. doi: 10.1080/21548331.2015.1085797
Bell C, Kurosky SK, Candrilli SD. Muscular dystrophy-related hospitalizations among male pediatric patients in the United States. Hospital Practice. 2015 Aug;43(3):180-5.
Bae JP, Candrilli SD, Fortenberry J, Meyers JL, Jakubowski JA, Drenning D. Point-of-care platelet reactivity determination with VerifyNow-P2Y12® following administration of clopidogrel or prasugrel: data from a real-world, clinical-care inpatient setting. Hospital Practice. 2014 Oct;42(4):7-15. doi: 10.3810/hp.2014.10.1139
Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011 Feb 14;171(3):218-25.
Simpkins J, Divine G, Wang M, Holmboe E, Pladevall-Vila M, Williams LK. Improving asthma care through recertification: a cluster randomized trial. Arch Intern Med. 2007 Nov 12;167(20):2240-8.
Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007 Feb 12;167(3):290-5.
Offen W, Chuang-Stein C, Dmitrienko A, Copley-Merriman K. Multiple co-primary endpoints: medical and statistical solutions: a report from the multiple endpoints expert team of the PhRMA. Drug Inf J. 2007;4:31-46.
Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley DJ, Mangel AW. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001 Jul 23;161(14):1733-40.
Backhouse ME, Gnanasakthy A, Schulman KA, Akehurst R, Glick H. The development of standard economic datasets for use in the economic evaluation of medicines. Drug Inf J. 2000;34(4):1273-91.
Ciociola AA, Webb DD, McSorley DJ. The continued use of placebo-controlled clinical trials in the study of peptic ulcer disease: a sponsor perspective. Drug Inf J. 1996 Apr;30(2):433-9.
Doward LC. Developing a measure of quality of life for patients with recurrent genital herpes. Drug Inf J. 1994 Jan 1;28(1):19-25.
Koch GG, Amara LA, Forster JK, McSorley DJ, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993 Jul;27(3):805-24.
Bollini P, Garcia Rodriguez LA, Perez GS, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med. 1992 Jun 1;152(6):1289-95.
Jick H, Porter J, Morrison AS, Rothman KJ. Lung cancer in young women. Arch Intern Med. 1979 Jul 1;139(7):745-6.